Swiss Rockets Announces Strategic Exclusive License Acquisition of Cutting-Edge Sequencing Technology from MGI Tech and Complete Genomics

The agreement grants Swiss Rockets a perpetual, transferable and sublicensable, freedom-to-operate licence for the United States of America, Europe, Latin America, Africa and Central Asia. There is an option to expand the rights into the Asia-Pacific region in 2026. The agreement covers the patents and other intellectual property necessary for development, manufacturing, and sales of the next-generation CoolMPS sequencing platform, which will provide faster, cheaper, and more accurate whole genome sequencing and other omics tests. The agreement includes payments linked to technology transfer and revenue-based royalties.

Swiss Rockets’ future development will focus on advancing CoolMPS products with innovative read barcoding. These innovations will support comprehensive omics testing for advanced genomic research and molecular health monitoring.

CoolMPS chemistry provides the most advanced MPS/NGS technology, generating cost-effective Sanger sequencing quality reads of 600-700 bases. It also enables the most accurate typical 150-200 bases reads. When combined with proprietary co-barcoding libraries, the CoolMPS offering provides complete haplotype-phased genome, transcriptome and microbiome sequencing for both disease prevention and optimal treatment selection, including in the field of cancer detection.

When combined with a special sequencing library for cell-free dsDNA, it enables the most accurate WGS-based early cancer detection and MRD. This allows both original strands to be sequenced in one DNA nanoball eliminating almost all false somatic mutations due to DNA damage, amplification and sequencing errors.

The first CoolMPS sequencers, which allow for cost-effective SE600+ reads for new applications such as CompleteWGS, CompleteTranscriptome and CompleteMicrobiom are scheduled for early access in Q1 2026.

This exciting deal between Swiss Rockets, MGI and Complete Genomics will help us to further develop our CoolMPS technology and achieve our vision of enabling longer healthy living through omics for all. “This is a dream come true for me”, said Dr Rade Drmanac, Chief Scientific Officer of MGI and Founder of Complete Genomics. “We now have everything needed to utilise the full potential of our cutting edge CoolMPS technology.”

“This strategic licence partnership with MGI and Complete Genomics perfectly complements Swiss Rockets’ advanced precision therapeutic development companies, said Dr. Vladimir Cmiljanovic, Founder, CEO and Chairman of Swiss Rockets. “It enables us to provide affordable, accurate and informative multi-omics tests for preventive health and early diagnostics, as well as effective precision medicine and longevity treatments.”